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Abstract
After atrial fibrillation, heart failure is the second most
frequent cardiac association of stroke. Deteriorating left
ventricular systolic function appears to increase the risk of
cardioembolic stroke in heart failure. Age, hypertension and
prior stroke are also risk factors for stroke in heart failure. Since
these are risk factors for cerebral and other vascular disease
rather than for cardioembolism, embolism may not be the sole
pathogenesis of stroke in heart failure. Hypoperfusion as a cause
of cerebral injury is suggested by a reduction of blood flow and
autoregulatory capacity in severe heart failure. An increase in
cerebral infarct volume and impaired cognition in patients with
left ventricular systolic dysfunction also supports this. There is
a need for further research to define how the brain is affected
by progressive cardiac failure and to determine which
echocardiographic and other vascular risk factors best indicate
an increased stroke risk.
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Ejection fraction (EF) is the proportion of left ventricular
volume emptied during ventricular systole.  It is a reliable
measure of left ventricular systolic function that can be assessed
non-invasively by echocardiography or by gated radionuclide
scanning; the normal value is 50-70%.  When left ventricular
systolic function is impaired, EF declines unless there is a
corresponding reduction in workload, as occurs in states of
peripheral vasodilatation or valvular regurgitation.
Consequences of low EF include elevated left ventricular filling
pressure and a fall in stroke volume that reduces systemic blood
flow.  Peripheral vasoconstriction often develops to a degree
beyond that required to compensate for the fall in cardiac output
and maintain blood pressure. Furthermore, the reduced stroke
volume creates a condition of relative stasis within the left
ventricle that may activate coagulation processes and increase
the risk of thromboembolic events.
Although patients with low EF are prone to hemodynamic
decompensation, clinical heart failure is not invariably present.
Conversely, cardiac failure may occur in patients with a normal
ejection fraction, particularly when the diastolic relaxation
properties of the left ventricle are impaired as in cases of
hypertrophic cardiomyopathy.
The term cardiomyopathy refers to a group of diseases of
myocardium that impair cardiac performance.  The etiology of
cardiomyopathy may be ischemia or infarction on the basis of
coronary artery disease, or nonischemic as a result of genetic or
acquired defects of myocardial cell structure or metabolism.
Ischemic cardiomyopathy is particularly common among
diabetics and others prone to atherosclerosis, whereas
nonischemic cardiomyopathy may result from exposure to
toxins like alcohol or viral infection.
Congestive heart failure is a clinical syndrome characterized
by varying degrees of dyspnea, abnormal fluid accumulation
and fatigue.  Traditionally, stratification of the severity of
functional impairment due to heart failure in clinical studies is
based on the New York Heart Association (NYHA) classification.
This simply translates tolerance of physical activity such that
NYHA class IV refers to heart failure symptoms at rest, class III
patients have symptoms on mild exertion, class II have
symptoms with moderate effort, and with class I the patient is
asymptomatic except at extremes of effort.
10 Malta Medical Journal     Volume 16   Issue 04   November 2004
Stroke in patients with impaired left
ventricular function
Cardiac disease is a major independent risk factor for stroke,
ranking third after age and hypertension.  In the USA, atrial
fibrillation is the most frequent cardiac disorder associated with
stroke. Cardiac failure ranks second as a cause of stroke,
although it affects about twice the number of individuals in the
population than are affected by atrial fibrillation. This is because
the rate of stroke in cardiac failure is substantially lower in heart
failure (1.6% per year) than in atrial fibrillation (about 5% per
year).  Atrial fibrillation carries an overall four-fold relative risk
of stroke.1 The relative risk of stroke associated with congestive
heart failure is also about fourfold among persons 50 to 59 years
of age but diminishes to about x 1.5 by age 80 to 89 years.2 The
risk of stroke is slightly higher among men with cardiac failure
than women, but impaired left ventricular function (as
measured by low EF) may be a more powerful risk factor for
stroke in women.3 This may reflect sex-related differences in
the pathogenesis of heart failure4 and consequently of stroke in
patients with heart failure. Patients with cardiac failure who
have had a stroke have a much higher subsequent stroke rate:
45% five-year (average 9% per year) recurrent stroke rate.5
Echocardiographic markers for mural
thrombus and embolism
Several echocardiographic markers of ventricular thrombus
formation and thromboembolism have been defined in patients
with heart failure. Left atrial end-systolic internal diameter and
left ventricular internal end-systolic dimension are greater in
patients with left ventricular thrombus and EF, fractional
shortening, mitral regurgitation jet area and the ratio of mitral
regurgitation jet area to left atrial area are significantly
decreased in patients with LV thrombus6 (Table 1). These
findings suggest that both the left atrium and the left ventricle
may give rise to thrombi in heart failure. Ischemic etiology and
decreasing ejection fraction were the only two risk factors for
systemic embolization in another echocardiographic study7
(Table 2). Two large studies found the rate of stroke to be
inversely proportional to EF.3,8  In the Survival and Ventricular
Enlargement (SAVE) study,8 patients with EF 29-35% (mean
32%) had a stroke rate of 0.8% per year; the rate in patients
with EF <28% (mean 23%) was 1.7% per year.  There was an
18% increment in the risk of stroke for every 5% decline in EF
(Figure 1).  These findings apply mainly to men, who represented
Table 1: Echocardiographic findings in 103 patients with dilated cardiomyopathy6
Finding No LV thrombus LV thrombus p-value
(n=91) (n=12)
LA end systolic diameter (mm) 44 ± 1 50 ± 2 0.03
LV end systolic internal dimension (mm) 56 ± 0.8 60 ± 1 0.04
LV end diastolic internal dimension- (mm) 66 ± 0.6 66 ± 1.0 NS
Interventricular septum thickness (end diastolic) (mm) 12 ± 0.4 12 ± 0.7 NS
LV posterior wall thickness- end diastolic (mm) 11.9  ± 0.3 12.3 ±0.9 NS
Ejection fraction (%) 22 ± 0.8 13 ± 0.9 0.001
Fractional Shortening (%) 15 ± 0.6 11 ± 2 0.03
Mitral regurgitation jet area (cm2) 6.2 ± 0.6 3.0 ± 1 0.04
Left atrial area (cm2) 24.6 ± 1 28 ± 2 NS
Ratio (MR jet area/LA area) 0.26 ± 0.1 0.11 ± 0.1 0.02
Mitral regurgitation:
    None (n [%]) 42 [46] 5 [42] NS
    Any MR 49 [54] 7 [58] NS
    Mild 18 [20] 5 [42] NS
    Moderate 20 [22] 2 [17] NS
    Severe 11 [12] 0 NS
Figure 1: Stroke rate by ejection fraction8
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over 80% of trial participants. A retrospective analysis of data
from Studies of Left Ventricular Dysfunction (SOLVD)3, which
excluded patients with atrial fibrillation, found a 58% increase
in risk of thrombo-embolic events for every 10% decrease in EF
among women (p=0.01).  There was no significant increase in
stroke risk among men in that trial (Table 3). The stroke rate
was about 1.4% per year in men with EF ≥30%. In women the
stroke rate was 1.4% per year with EF 21-30% increasing to 2.4%
per year with EF ≤10%.3
Stroke Subtype and vascular risk factors
in heart failure
Cardiogenic embolism is thought to be the principal cause
of stroke in patients with heart failure. About twelve percent of
patients with cardiomyopathy have left ventricular thrombi on
echocardiography.6 In nonischemic dilated cardiomyopathy,
stasis of blood in the poorly functioning left ventricle is thought
to predispose to ventricular thrombus formation. Impaired left
ventricular function or clinical congestive heart failure increase
the risk of stroke in patients with atrial fibrillation.9  In ischemic
cardiomyopathy, regional ventricular asynergy is a potential
source of cardioembolic stroke. Patients with ischemic
cardiomyopathy however, often have vascular risk factors  and
atherosclerosis of the arteries supplying the brain. Although
vascular risk factors are not known to be direct risk factors for
cardiogenic embolism, they appear to be important risk factors
for stroke in heart failure. In patients with heart failure without
atrial fibrillation, SOLVD found that in men, every 10 years
increase in age increases the risk of thromboembolism by a
relative risk of 1.3, a history of hypertension also increases the
risk of stroke by 1.3, diabetes increases the risk by 1.7 and prior
stroke by a risk factor of 2.6. In women with heart failure but
without atrial fibrillation, the relative risk of stroke is increased
by diabetes (x2.3) and smoking history (x2.4) (Table 4).3 The
way by which these risk factors increase the risk of stroke in
heart failure is unclear. Patients with these risk factors have a
high prevalence of systemic, cervical and cerebral arterial
Table 2: Multivariate predictors of systemic embolization
in severe LV dysfunction7
Predictors Odd Ratio p-value
(18/114pts)
Ischemic etiology 3.79 (1.13-12.64) 0.03
EF% 0.91 (0.82-1.00) 0.04
LVIDD,mm 1.04 (0.98-1.10) 0.18
Age, yr 1.03 (0.97-1.08) 0.38
Apical aneurysm 2.46 (0.40-14.99) 0.56
Atrial fibrillation 1.19 (0.26-5.41) 0.82
Male gender 0.87 (0.22-3.42) 0.84
Table 3: Low EF and thromboembolism3
LVEF Incidence RR (95% CI)
Men (n=5,457)
  ≥30% 1.70 1.00
  21%-30% 1.83 1.08 (0.83-1.41)
  11%-20% 2.01 1.21 (0.86-1.70)
  ≤10% 1.96 1.21 (0.30-4.92)
Women (n=921)
≥30% 1.78 1.00
  21%-30% 2.41 1.35 (0.74-2.47)
  11%-20% 3.80 2.17 (1.10-4.30)
  ≤10% 4.20 2.43 (0.32-18.26)
Adapted, with permission, from Dries et al. (13). CI=confidence
interval; LVEF=left ventricular ejection fraction; RR=relative risk
Table 4: Relative Risk of thrombo-embolic events by gender in studies of left ventricular dysfunction3
Men (n=5,457) Women (n=958)
      RR (95% CI) p-value RR (95% CI) p-value
Age, per decade 1.29 (1.12-1.48) 0.007 1.07 (0.80-1.42) 0.27
EF, per 10% decrease 0.99 (0.81-1.22) 0.95 1.47 (0.97-2.23) 0.07
History of hypertension 1.30 (1.00-1.69) 0.05 1.04 (0.57-1.88) 0.90
Smoking history, yes/no 0.93 (0.68-1.28) 0.65 2.42 (1.24-4.72) 0.01
Diabetes, yes/no 1.71 (1.29-2.28) 0.0002 2.32 (1.24-4.34) 0.009
Previous CVA 2.58 (1.78-3.76) 0.0001 2.34 (0.96-5.71) 0.06
Previous MI 0.77 (0.57-1.03) 0.08 0.75 (0.41-1.36) 0.34
Enalapril vs placebo 0.80 (0.62-1.04) 0.09 0.67 (0.38-1.21) 0.18
Antiplatelet monotherapy 0.71 (0.53-0.94) 0.02 0.37 (0.18-0.84) 0.84
Anticoagulant monotherapy 0.92 (0.59-1.42) 0.69 1.09 (0.44-2.71) 0.84
Antiplatelet and anticoagulant 1.53 (0.80-2.93) 0.21 2.98 (0.67-12.39) 0.15
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disease with the potential for cervical or intracranial stenosis
and impairment of autoregulation. There may be interplay
between severity of arterial disease and decreased cerebral
perfusion in these patients. In patients with atrial fibrillation
or with recent myocardial infarction, increasing age, prior
stroke, hypertension and diabetes, increase the risk of stroke
(Table 5).9 These data suggest that not all strokes in patients
with cardiac failure are of cardioembolic origin.
Hypoperfusion-related cerebral ischemia
Hypoperfusion as a cause of cerebral injury in heart failure
is supported by 133Xenon studies10  that show a lower cerebral
blood flow in patients with cardiac failure than in controls. The
brain is protected from normal variations in systemic blood
pressure by autoregulation, which maintains cerebral blood flow
constant unless systemic hypotension is severe. Blood pressure
is usually well-maintained in heart failure, but patients with
severe left ventricular systolic dysfunction are prone to transient
hypotension secondary to cardiac ischemia, arrhythmia or
overmedication. Cerebral injury from hypoperfusion may still
occur without systemic hypotension if cerebral autoregulation
is impaired. Autoregulation appears to be increasingly impaired
as patients progress from NYHA class I to class IV cardiac
failure. 11 Old age, recent stroke or severe carotid occlusive
disease also impair cerebral autoregulation in patients without
cardiac failure, and patients with cardiac failure who fall into
these categories may be particularly at risk for hypoperfusion-
related cerebral ischemia.
In order to determine if high-grade cervical or intracranial
arterial stenosis increases the risk for hypoperfusion-related
cerebral ischemia in patients with heart failure, we compared
mean infarct volume on CT or MR hard-copy images between
Table 5: Risk factors for cardiogenic embolism
Risk Factor Atrial Myocardial LV Systolic
Fibrillation9 Infarction32 Dysfunction
Hypertension + + +
Diabetes + + +
Prior  stroke + + +
Age + + +
Prior MI +/- - +
serial patients with cardiac EF 35% who had high-grade (≥70%)
carotid artery stenosis and a control group of serial patients with
normal cardiac EF and ≥70% carotid artery stenosis. In the
patients with high-grade carotid stenosis, the mean volume of
infarcts ipsilateral to the stenosis was greater in patients with
low EF (74.7ml; 95% CI: 17.3-132.1ml) than in patients with
normal EF (17.1ml; 95% CI: 9.4-24.8ml) using all infarct types
(p<0.05).  Frequency of hypertension was the same in these
two groups suggesting that low cardiac output may directly cause
cerebral hypoperfusion distal to high grade arterial stenosis
(Figure 2). We did not find a difference in the number of infarcts
between the two groups which suggested that hypoperfusion
secondary to low cardiac output tends to increase the size of
infarcts caused by other mechanisms, rather than produce
infarcts de novo.
Progressive cerebral injury
and “circulatory” dementia
There is evidence of progressive cerebral injury in patients
with heart failure. A higher frequency of cortical and ventricular
Figure 2: Watershed cerebellar infarct in patient with ejection fraction 30% and hypoplastic vertebral artery
b)  Magnetic resonance brain scan showing a linear
infarct (arrow) in the watershed between the areas
of supply of the medial and lateral branches of the
posterior inferior cerebellar artery, ipsilateral to the
stenosed vertebral artery shown in (a)
a) Magnetic resonance angiogram of circle of Willis
showing hypoplastic stenosed vertebral artery
with posterior inferior cerebellar artery
originating from it (arrow)
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atrophy is seen in patients with cardiomyopathy.12,13 Cardiac
failure may also be a risk factor for white matter periventricular
ischemic lesions on brain CT scans. A magnetic resonance
spectroscopy study found cerebral metabolic abnormalities
including the occipital N-acetylaspartate level to be powerful
predictors of cardiac mortality,14 establishing a new, important
link between cardiac and cerebral dysfunction. These data
suggest that as cardiac output decreases, the severity of resulting
brain injury mirrors the severity of cardiac disease.
Cognitive impairment is being increasingly recognized as
an important complication of heart failure. Patients with
end-stage heart failure awaiting heart transplantation have a
high frequency of cognitive impairment.15 Cardiac rehabilitation
patients have a high frequency of cognitive impairment. 16 It is
unclear from these studies whether the cognitive impairments
were due to multiple cerebral emboli or cerebral hypoperfusion.
Two studies which excluded obvious stroke, however, suggested
that stroke is not necessary to produce cognitive impairment.
The first of these found a correlation between the Mini Mental
State Examination score and left ventricular ejection fraction
in elderly (mean 76.7 years) patients with chronic heart failure.17
A second population study of patients 65 and older found that
cardiac failure is independently associated with cognitive
impairment.18  These studies suggest that hypoperfusion alone
may cause cognitive impairment in heart failure. This is also
supported by a recent study that found an association between
systolic hypotension and cognitive impairment in older patients
with heart failure.19
Memory and attention deficits appear to be the most
frequent cognitive deficits seen in heart failure patients followed
by slowed motor response time and difficulties in problem
solving.20 Verbal memory deficits increase with worsening heart
failure class.21 Improvement in cognition has been noted
following cardiac transplantation.15 Since heart failure affects
some 4.5 million Americans and heart failure and cognitive
impairment are frequent among elderly discharged from
hospital,22 “Circulatory Dementia” 16 may be a major
unrecognized contributor to cognitive impairment in the elderly.
Cerebral blood flow may improve with angiotensin converting
enzyme inhibitors10,23,24 and further studies are needed to
determine the prevalence of “circulatory dementia” and to
evaluate any therapeutic options.
Anticoagulation in patients
with cardiac failure
One of longest-standing unanswered questions in cardiology
is whether warfarin is indicated for stroke prevention in patients
with heart failure. The place of anticoagulation in patients with
heart failure has been controversial since the early 1950s when
three randomized controlled studies of coumarin
anticoagulants25-28 suggested a marked reduction in pulmonary
embolism, a halving of mortality and a reduction of
thromboembolic events and stroke. The lack of proper
randomization, inclusion of patients with atrial fibrillation and
lack of CT imaging however, makes those studies inadequate as
a basis to recommend anticoagulation. Since the stroke rate is
so low in heart failure (1.6% per year compared with 5% per
year in atrial fibrillation), a very large and expensive study
(around 8,000 patients) is theoretically needed to determine
whether warfarin reduces stroke in heart failure. Routine
chronic use of warfarin in patients with reduced ejection fraction
would require that the benefits of warfarin outweigh its
hemorrhagic risks. The rate of intracerebral hemorrhage is about
0.3% per year with warfarin and about 0.2% with aspirin.29 Even
if warfarin reduced stroke by 50% over aspirin (the rate found
in atrial fibrillation studies), since the stroke rate is so low in
heart failure, one could only achieve a 0.5% absolute reduction
in stroke rate per year, meaning that 200 patients would need
to be treated with warfarin for a year to save one stroke. Even if
a statistically significant “biological” effect of warfarin was found
over aspirin, this very small absolute risk reduction is clearly
not clinically relevant. Cardiologists and internists however
continue to anticoagulate patients with heart failure without
proper (Class III) clinical trial evidence of a clinically relevant
effect of warfarin.
The SAVE study linked stroke risk with low ejection fraction,
suggesting that ejection fraction can be used to select patients
with cardiac failure at higher risk for stroke.8 The Warfarin
Antiplatelet Treatment in Chronic Heart Failure (WATCH) was
the first modern randomized controlled study of anticoagulation
in heart failure. Patients with ejection fraction 35% and heart
failure but without atrial fibrillation were randomized to
warfarin, aspirin or clopidogrel. The study was terminated
prematurely due to inadequate recruitment, but showed a
significant reduction in stroke with warfarin compared to
antiplatelet therapy with a hazard ratio of about 0.4. In the
warfarin arm of the study, the stroke risk reduction was largely
offset by intracerebral hemorrhages. Due to the small number
of patients enrolled, the statistical power of the study was
insufficient to allow the results to be used as a basis for
establishing guidelines for anticoagulation use in heart failure.
WATCH also showed a significant reduction in heart failure
hospitalizations with warfarin over aspirin but showed no
difference in mortality between warfarin and aspirin or
clopidogrel. A further definitive study is needed to determine
whether anticoagulation should be used in heart failure patients.
The Warfarin versus Aspirin in Reduced
Cardiac Ejection Fraction (WARCEF) study
The WARCEF study is a National Institutes of Health
randomized, double-blind controlled clinical trial with a target
enrollment of 2,860 patients. WARCEF is comparing a
combined primary endpoint of stroke, death and intracerebral
hemorrhage between warfarin (INR 2.5-3) and aspirin (325 mg)
with a 90% statistical power. Patients with low (≤35%) cardiac
ejection fraction are eligible in all New York Heart Association
classes (I to IV). 20% of patients will have a stroke or TIA within
12 months prior to randomization. Since patients with prior
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stroke have a much higher stroke rate than patients without
prior stroke (9% versus 1.6%), the inclusion of these patients
should increase the number of stroke endpoints in the study
and allow the detection of a “biological” effect of one medication
over the other on stroke with the 2,860 patient sample size.
Randomized patients receive either active warfarin and
placebo aspirin or active aspirin and placebo warfarin. The study
is double blinded: all patients receive regular blood draws for
INR evaluation. Patients randomized to active aspirin have INR
results that are fabricated by a computer-based algorithm to
appear as if they were taking warfarin. Treating clinicians receive
and adjust INR results for patients on both warfarin and aspirin
and manage all patients as if they were on active warfarin. 30 31
In addition to detecting a “biological” effect of warfarin or
aspirin on stroke, the study will look for subgroups of patients
with higher stroke risk, (for example patients with very low
ejection fraction, prior stroke, hypertension), in whom there is
a clinically relevant stroke risk reduction. On completion of
WARCEF, the results will also be amalgamated with the WATCH
study results. Together, the results of these trials will attempt
to define the place of antithrombotics in heart failure.
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